Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Gautschi, O; Huegli, B; Ziegler, A; Gugger, M; Heighway, J; Ratschiller, D; Mack, P C; Gumerlock, P H; Kung, H J; Stahel, R A; Gandara, D R; Betticher, D C (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer letters, 254(2), pp. 265-73. Amsterdam: Elsevier 10.1016/j.canlet.2007.03.008

Full text not available from this repository.

Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Service Sector > Institute of Pathology
UniBE Contributor:	Gautschi, Oliver, Gugger, Mathias, Ratschiller, Daniel
ISSN:	0304-3835
ISBN:	17449174
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:53
Last Modified:	05 Dec 2022 14:16
Publisher DOI:	10.1016/j.canlet.2007.03.008
PubMed ID:	17449174
Web of Science ID:	000249141500009
URI:	https://boris.unibe.ch/id/eprint/22405 (FactScience: 34538)